License agreement on NK cell therapy technology
This agreement will bring significant benefit to the targeted treatment of patients suffering from cancer. The agreement not only opens up new opportunities for the development of NK-antibody combination therapies but also has a significant positive impact on the production time of Glycostem’s lead product oNKord® and its second (CAR-NK) and third (TCR-NK) generation therapies – viveNK™. Read the whole press release here.
Back
Related news
2020 highlights Pivot Park Community
Read here a short summary of the 2020 highlights of our Community members
View article
Press release Glycostem
12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.
View article
GLYCOSTEM signs two commercialisation agreements with Korean partner
OSS, Netherlands — On 9 September 2019 Glycostem and an undisclosed Korean partner confirmed the signing of two agreements. The...
View article